Thrombotargets Europe SL is a privately held clinical stage biotech Company, intensive in R&D, founded in 2005.
Thrombotargets is focused on the development of new therapeutical compounds in the hemostasis and coagulation field. Its proprietary technologies and expertise have led to an innovative pipeline. The topical hemostat TT-173, Thrombotargets lead compound, is at present in clinical Phase III.
Thrombotargets’ headquarters are in Castelldefels, close to Barcelona, where part of the R&D is carried out. Part of its R&D activities are based at the National Center of Technology, in Madrid.